Fulcrum Therapeutics (FULC) EBIT Margin (2020 - 2024)
Fulcrum Therapeutics' (FULC) quarterly EBIT Margin came in at 65.61% in Q2 2024, up 316698.0% year-on-year from N/an in Q3 2023, and up 102.04% on a QoQ basis from 3213.78% in Q4 2023.
Fulcrum Therapeutics (FULC) EBIT Margin (2020 - 2024) Analysis & Trends
Fulcrum Therapeutics (FULC) has 5 years of EBIT Margin data on file, last reported at 65.61% in Q2 2024.
- On a quarterly basis, EBIT Margin rose 316698.0% year-over-year to 65.61% in Q2 2024; TTM through Jun 2025 was 105.97%, a 6582.0% decrease from a year earlier, with the FY2024 full-year figure at 27.37%, up 391787.0% from the prior year.
- EBIT Margin for Q2 2024 stood at 65.61%, up from 3213.78% in the prior quarter.
- Over the last five years, EBIT Margin for FULC reached as high as 65.61% in Q2 2024 and fell as low as 9471.19% in Q1 2023.
- Historically, EBIT Margin has averaged 2044.08% across 5 years, with a median of 1033.77% in 2020.
- Across the five-year window, EBIT Margin sank 846818 bps in 2023 and jumped 316698 bps in 2024, its largest moves.
- Year by year, EBIT Margin stood at 420.99% in 2020, then slipped by 11 bps to 465.78% in 2021, then sank by 777 bps to 4083.65% in 2022, then increased by 21 bps to 3213.78% in 2023, then soared by 102 bps to 65.61% in 2024.
- Per Business Quant data, the three most recent EBIT Margin figures were 65.61% in Q2 2024, 3213.78% in Q4 2023, and 3615.28% in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 16.51% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 30.35% |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Fulcrum Therapeutics | 285.43 Mn | 285.43 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 65.62% |
| Dec 31, 2023 | -3,213.78% |
| Sep 30, 2023 | -3,615.28% |
| Jun 30, 2023 | -3,101.36% |
| Mar 31, 2023 | -9,471.19% |
| Dec 31, 2022 | -4,083.65% |
| Sep 30, 2022 | -2,058.75% |
| Jun 30, 2022 | -1,819.08% |
| Mar 31, 2022 | -1,003.01% |
| Dec 31, 2021 | -465.78% |
| Sep 30, 2021 | -420.87% |
| Jun 30, 2021 | -449.26% |
| Mar 31, 2021 | -355.88% |
| Dec 31, 2020 | -420.99% |
| Sep 30, 2020 | -1,033.77% |
| Jun 30, 2020 | -796.20% |
| Mar 31, 2020 | -2,506.13% |